The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

AURORA, Colo., Oct. 28, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking ...

Peking University scientists have developed a cancer therapy that could make life-saving treatment accessible to any patient, anywhere. A team led by Professor Wei Wensheng from Peking University, ...

The findings, published in the New England Journal of Medicine by Robert Chiesa of Great Ormond Street Hospital for Children ...

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana ...

LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...

A new type of allogeneic CAR-T cell immunotherapy that targets aggressive blood cancers has shown promising results alongside manageable side effects, according to the results of an international ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

Forbes contributors publish independent expert analyses and insights. I'm a senior tech contributor who writes about science and technology Multiply Labs and Universal Robots have entered a ...

Corynebacterium glutamicum S9114, a superior strain widely used in glutamic acid industrial production through traditional mutagenesis screening, is ...